SIRT1 and cancer: It is noteworthy that the FOXO3-associated signaling pathways have been recognized as therapeutic targets for various cancers (Orea-Soufi et al. 2022), and our research findings provide a novel mechanistic understanding of SIRT1 as an upstream regulatory factor.